Figures
UK hypertension treatment guidelines consider ethnicity (Black or non-Black) as a determinant of treatment choice. However, evidence from randomised controlled trials of the effectiveness and risks of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors in different ethnic groups is lacking. Using primary care data from self-reported Black, South Asian, and White patients at high risk of cardiovascular disease in England, Paris J. Baptise and colleagues apply reference trial emulation methods to assess the ‘real-world’ generalisability of results from the ONTARGET trial to trial-underrepresented groups.
Image Credit: Joanna Zduńczyk, Pexels
Citation: (2024) PLoS Medicine Issue Image | Vol. 21(9) October 2024. PLoS Med 21(9): ev21.i09. https://doi.org/10.1371/image.pmed.v21.i09
Published: October 15, 2024
Copyright: © 2024 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
UK hypertension treatment guidelines consider ethnicity (Black or non-Black) as a determinant of treatment choice. However, evidence from randomised controlled trials of the effectiveness and risks of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors in different ethnic groups is lacking. Using primary care data from self-reported Black, South Asian, and White patients at high risk of cardiovascular disease in England, Paris J. Baptise and colleagues apply reference trial emulation methods to assess the ‘real-world’ generalisability of results from the ONTARGET trial to trial-underrepresented groups.
Image Credit: Joanna Zduńczyk, Pexels